-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4043 Chemical Modulation of ELF1 Binding to RUNX1 Target Genes Leads to Increased Hematopoietic Stem Cell Self-Renewal

Program: Oral and Poster Abstracts
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science
Monday, December 9, 2024, 6:00 PM-8:00 PM

Anne L. Robertson1*, Lu Yue, PhD1*, Avik Choudhuri, PhD2*, Caroline Kubaczka, PhD3*, Samuel J. Wattrus, PhD1,4*, Joseph Mandelbaum, PhD5*, Serine Avagyan, MD, PhD6, Song Yang, PhD7*, Rebecca J. Freeman1*, Victoria Chan1*, Megan C. Blair1*, George Q. Daley, MD, PhD8 and Leonard I. Zon, MD7

1Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute; Howard Hughes Medical Institute; Harvard Medical School; Harvard Stem Cell Institute; Harvard University, Boston, MA
2Fulcrum Therapeutics, Cambridge, MA
3Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute; Harvard Medical School; Harvard University, Boston, MA
4Department of Molecular Biology, Massachusetts General Hospital, Boston
5Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute; Howard Hughes Medical Institute; Harvard Medical School; Harvard Stem Cell Institute; Harvard University, Boston
6University of California San Francisco, San Francisco, CA
7Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital; Howard Hughes Medical Institute; Harvard Medical School; Harvard Stem Cell Institute; Harvard University, Boston, MA
8Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA

Hematopoietic stem cell (HSC) expansion and self-renewal are important for stem cell therapy. Expanding HSCs ex vivo remains challenging. To identify novel compounds that increase HSCs, we screened 3,840 small molecules using a zebrafish blastomere culture screening system with a HSC specific Runx1+23:GFP reporter and identified a RUNX1/CBFβ modulator, Ro5-3335, which increases Runx1+ cells. Using spinning disk confocal time-lapse imaging in live zebrafish embryos, we found that Ro5-3335 treatment increases HSC number as much as 1.79 fold (p<0.0001) and significantly increases HSC divisions (5 vs 3.5 divisions, p=0.009) in the stem cell niche during early hematopoiesis. Transplantation of Ro5-3335 treated Runx1+ cells into zebrafish embryos revealed enhanced engraftment by 1.60 fold (p<0.001). To determine whether the increased HSC production during development increases HSC clones in adulthood, we used a brainbow color barcoding system to lineage trace each HSC and its blood progenies. Treatment of Ro5-3335 during definitive hematopoiesis significantly increases HSC clones in adulthood (23 vs 18.6 clones, p<0.0001). To determine whether the effect of Ro5-3335 on HSC expansion is conserved in mammalian systems, we cultured human CD34+ HSPCs and found that Ro5-3335 promotes CD34+CD38-CD45RA-CD90+ HSC expansion in 6-day ex vivo culture (20.3 vs 15.8 fold (p=0.0157)). RUNX1 is an important transcription factor for HSC proliferation and differentiation. Chromatin immunoprecipitation sequencing (ChIP-seq) of RUNX1 showed that Ro5-3335 treatment increased RUNX1 binding to target genes in human CD34+ HSPCs, independent of CBFβ binding. Motif analysis of the genes with increased RUNX1 binding and increased transcription suggested binding of ELF family transcription factors to RUNX1 target genes upon Ro5-3335 treatment. ELF1 ChIP-seq confirmed that ELF1 has increased binding to RUNX1 targets, including cell cycle genes CDC45, CDC37L, CCND2, and CCND3 upon Ro5-3335 treatment. Knocking down Elf2b in zebrafish embryos abolished the effect of Ro5-3335 both on HSC expansion and HSC clonality. Together, our studies provide the first evidence to show that it is possible to pharmacologically increase stem cell clonality in vivo.

Disclosures: Choudhuri: Fulcrum Therapeutics: Current Employment. Kubaczka: ElevateBio: Research Funding. Mandelbaum: Bristol-Myers Squibb: Current Employment. Zon: Fate Therapeutics: Current holder of stock options in a privately-held company; Scholar Rock: Current holder of stock options in a privately-held company; CAMP4 Therapeutics: Current holder of stock options in a privately-held company; Triveni Bio: Current holder of stock options in a privately-held company.

*signifies non-member of ASH